News & Events

In this section

Published originally by Logos Technologies prior to Instem ownership, included here for information purposes

Logos Technologies Forms a Strategic Collaboration with MicroConstants China to Bring ALPHADAS® to China

14th May 2012

“We are delighted to form this partnership and look forward to expanding the use of ALPHADAS into new geographical areas and further developing the system for the Chinese market,” says Mark Cusack, vice president of global business development for Logos Technologies Inc. “The ability to capitalize on the multi-lingual capabilities of ALPHADAS is tremendously exciting.”

Over the past few years, MicroConstants China has worked with a number of Phase I clinical trial centers in China to improve their SFDA GCP compliance programs. “We are thrilled to be able to offer ALPHADAS EDC to our existing network of clinical trial centers and other Phase I units in China,” says Dr. Q. David Yang, chief executive officer of MicroConstants China. “The system will further improve their work flow, data management and compliance with GCP regulations.”

ALPHADAS, is an e-Source, pro-active EDC automation system designed specifically for early phase clinical trials. The system has achieved great success and is employed by clients large and small, from top 10 pharma to small and independent Phase I units, globally. Collaborating with MicroConstants China will enable Logos to further expand the adoption of their market proven EDC solution into China.

Logos Technologies Inc is a leading provider of world-class clinical trial solutions to pharmaceutical, biotechnology and clinical research organisations. ALPHADAS® is an eSource, proactive clinical trials system that is mobile, schedule-driven, and provides real-time bedside or station based direct data capture. It meets the changing demands and time sensitive nature of early phase trials while integrating with clinical and laboratory operations. It accelerates data throughput, and enhances data integrity. 

MicroConstants China Inc. is a bioanalysis and early stage clinical trial Contract Research Organization (CRO) that was established in 2007 by the founder and president of MicroConstants, Inc., a bioanalytical and pharmacokinetic specialty CRO in San Diego, California with over a decade of GLP compliance history. Located in Beijing, MicroConstants China’s bioanalytical lab is the first in China to receive OECD GLP certification. Their integrated, early stage clinical trial management services include clinical site qualification, trial monitoring, clinical sample bioanalysis, data management, biostatistics, and clinical summary reports. MicroConstants China also provides QA auditing and GLP/GCP quality system consulting in China. 

About MicroConstants China

MicroConstants China Inc. is a bioanalysis and early stage clinical trial Contract Research Organization (CRO) that was established in 2007 by the founder and president of MicroConstants, Inc., a bioanalytical and pharmacokinetic specialty CRO in San Diego, California with over a decade of GLP compliance history. Located in Beijing, MicroConstants China’s bioanalytical lab is the first in China to receive OECD GLP certification. Their integrated, early stage clinical trial management services include clinical site qualification, trial monitoring, clinical sample bioanalysis, data management, biostatistics, and clinical summary reports. MicroConstants China also provides QA auditing and GLP/GCP quality system consulting in China.

Press Contact:

Instem
Angela King
angela.king@instem.com